Utah Medical Products Inc. (UTMD)
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
UTMD's Q2 earnings per share decline 10.1% year over year, while quarterly revenues face pressure from lost customers and slower new business growth.
Utah Medical's Q1 Earnings Fall Y/Y Due to Elevated Litigation Costs
UTMD reports a year-over-year decline in Q1 earnings per share and sales, pressured by lost distributor business and higher costs, despite improved margins and a strong balance sheet.
Utah Medical Gains 32% in a Year: Should You Buy the Stock?
UTMD's niche leadership, global footprint, and strong cash generation position it to benefit from rising demand for high-quality maternal and neonatal healthcare solutions.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
UTMD's Q4 earnings fall year over year due to weak OEM sales and lower international Filshie sales, but strong U.S. Filshie growth and steady margins help offset broader revenue pressure.
UTMD's Q3 Earnings Dip Y/Y on Trade Disruptions, Margins Squeeze
Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
Utah Medical Products: Deep Discount Is Drawing One Legendary Investor's Interest
I reiterate my strong buy on UTMD, citing its robust balance sheet, disciplined capital allocation, and 43% upside to my $82.22 price target. Revenue headwinds appear to be stabilizing, with legendary value investor Charles Brandes taking a 7.4% stake, signaling renewed institutional interest. Key risks include Filshie Clip litigation, declining China sales, and succession planning, but UTMD's undervaluation and cash reserves limit downside.
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1%
UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
Utah Medical Products: Favorably Skewed Risk/Reward Profile
UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share.
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S.
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales
UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.
